Search

everythinglearnresearchcommunity

for

Search:↓

User asks if applying Eucapil (fluridil) after minoxidil foam is possible. Seeks advice from others with experience.

This user has had 5 months of progress with treatments of Hims Topical .3% Finasteride and 6% Minoxidil, which seem to be helping their hair loss. Other users have given positive feedback on the results.

The conversation is about the anticipated release timeline for a hair loss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.

The conversation discusses a year-long hair loss treatment from February 28, 2022, to February 28, 2023, which included daily oral finasteride (1mg), biotin supplements, and the Curly Girl Method. Progress pictures were shared to show the results.

The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.

A user's experience with Dutasteride causing rapid hair loss and temple recession over 3 weeks, with other users offering advice about the potential causes of this.

A user's experience with early balding and their regimen of finasteride, minoxidil, microneedling, vitamin D, and biotin to treat it. Another user asked if the minoxidil had helped with regrowth before they started using it.

A 24 year old who has been experiencing thinning hair for 6 years and is starting a course of treatment involving finasteride, minoxidil, dermarolling, and nizoral shampoo. Others are wishing them luck and offering advice on how to potentially recover from the condition.

The user experienced significant hair regrowth using Minoxidil (Rogaine) and dermarolling twice a week. They also lost weight and improved their diet, which may have contributed to the results.

A 34-year-old male has been using Minoxidil for 9 years and Finasteride for 1 year, experiencing some shedding but overall hair improvement, especially at the crown. He is considering derma stamping for better tracking of temple progress.

Hair loss treatments like Minoxidil and Finasteride will still be used even if a cure is found. Hair transplants will continue as cloning new hair follicles will be part of the process.

The conversation discusses the potential of topical rapamycin, metformin, and alpha-ketoglutarate (a-KG) for hair growth, with skepticism expressed about their effectiveness based on personal experience and existing use. It also mentions AICAR, known as cardarine or GW, which is not suitable for long-term use due to cancer risks in animal studies and its similarity to metformin.

Researching and developing an effective local antagonist to block the androgen receptors for hair loss, as opposed to using DHT synthesis inhibitors that lower serum DHT levels. Several treatments such as CosmeRNA and Pyrilutamide are currently in development or undergoing trials.

The conversation is about personal experiences with Anagenic Pyrilutamid for hair loss and what carriers people use with it. No specific treatments or outcomes are mentioned.

The user is considering RU58841 and has been using dutasteride since age 17. They are seeking affordable SARD options, mentioning ASC-J9, GT20029, and AH001.

TDM-105795 is a potential hair growth stimulant that works differently from minoxidil and could be used alongside it for enhanced growth. It completed phase 2 trials in 2024, with a medium to high chance of release in 2026, but lacks recent updates or phase 3 trial information.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

KX-826 (Pyrilutamide) being tested in the US for hair loss treatment and that they have found enough people to participate in phase II clinical trials. Other treatments discussed are Minoxidil, finasteride, and RU58841.

The conversation is about using adenosine, finasteride, and minoxidil for hair loss treatment. The user ordered a 0.75% adenosine solution and is currently using finasteride 1mg and minoxidil 5%.

Vitamin D deficiency is linked to hair loss, and supplementation with vitamin D can improve conditions like androgenic alopecia and telogen effluvium. Users discussed various dosages of vitamin D, emphasizing the importance of getting blood tests to determine the appropriate amount.

A user experienced severe side effects from using topical minoxidil sublingually, including muscle cramps, dizziness, and high potassium levels. They were advised to stop and seek medical help, emphasizing that topical minoxidil is not safe for ingestion due to its alcohol content.

User shares 1-year progress using topical finasteride and minoxidil for hair loss, with positive results. Some users discuss trying topical dutasteride and varying dosages, while others share their experiences and ask about specific products.

A 26 year old female dealing with hair loss who is considering treatments such as Spiro, minoxidil and finasteride. Other potential solutions mentioned are PRP treatment, a wig, and bio-identical estrogen combined with bica.

Woman with telogen effluvium lost 40% of hair after traumatic event. Taking biotin, Viviscal Professional, and Rogaine 5% foam for treatment.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

RU58841's legitimacy and sourcing concerns. Users suggest caution and recommend trusted sources over platforms like Amazon.

Melatonin's effect on aromatase expression is unclear, with studies showing both increases and decreases. Hormonal impacts are complex and inconsistent, similar to changing health advice on other substances.

The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.

The relative strength of Pyrilutamide compared to RU58841 in terms of androgen receptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.